Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Casein Glycomacropeptide (CGMP) is a bioactive peptide derived from casein during cheese production. Recent research has explored its potential benefits in the management of Inflammatory Bowel Disorders (IBD), such as Crohn’s disease and ulcerative colitis. The rationale for its use is based on several properties: CGMP lacks phenylalanine (making it suitable for phenylketonuria patients), has prebiotic effects, modulates the gut microbiota, and exhibits anti-inflammatory properties in various models.

Preclinical studies, particularly in animal models, have shown that CGMP may help reduce intestinal inflammation, enhance gut barrier function, and favorably alter the gut microbial composition. For example, rodent studies have demonstrated that dietary CGMP can decrease the severity of colitis through downregulation of inflammatory cytokines and improvement of mucosal healing. Additionally, CGMP has been shown to promote the growth of beneficial bacteria such as Bifidobacteria.

However, evidence in humans is limited. Only a few small-scale clinical studies or pilot trials have investigated CGMP in IBD patients, and results have been promising but preliminary. No large randomized controlled trials currently confirm its efficacy or safety for IBD treatment. Therefore, the use of CGMP for IBD is justified by scientific investigation, but the strength of evidence remains low (rated 2/5), primarily due to the lack of robust human clinical data.

More about Casein Glycomacropeptide
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by Casein Glycomacropeptide

Products containing Casein Glycomacropeptide